Antibiotic Resistance Market Share, Size, Trends, Industry Analysis Report, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, and BSI); By Drug Class; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

Antibiotic Resistance Market Share, Size, Trends, Industry Analysis Report, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, and BSI); By Drug Class; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

The global antibiotic resistance market size is expected to reach USD 14.29 billion by 2032, according to a new study by Polaris Market Research. The report “Antibiotic Resistance Market Share, Size, Trends, Industry Analysis Report, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, and BSI); By Drug Class; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising proliferation of inappropriate use of antibiotics, such as over-prescription, consumption with proper medical supervision, and incomplete or improper treatment courses, all result in the development of antibiotic-resistant strains, driving the global market growth. Also, the growing need for the discovery of new antibiotics with the ability to effectively combat several antibiotic-resistant strains and R&D efforts focused on new drug classes are also likely to bode well for the market’s growth. For instance, in January 2023, Alkem Laboratories announced the launch of a new antibiotic drug for the treatment of multiple drug-resistant infections. This is a novel amalgamation of ceftazidime and avibactam, which is indicated for several ailments, including complicated urinary tract infections.

As whole-genome sequencing of the antimicrobial-resistant is being widely used for antimicrobial resistance surveillance, thereby, innovations in genome sequencing and different analysis technologies could revolutionize antibiotic resistance surveillance and epidemiology.

Furthermore, there is a growing focus on research and development activities or efforts to develop or discover new antibiotics, and various government authorities and health organizations are focusing on the methods to enhance antibiotic capabilities. Also, regulatory authorities are constantly working on raising awareness among the global population about antibiotic resistance and its health effects, which are likely to impact the market positively. For instance, in October 2023, The Quadripartite announced the creation of a new Working Group on Youth Engagement, especially for antimicrobial resistance. The members of the group will notify as well as guide quadripartite efforts to raise awareness and bring the younger population into the global AMR action.

Antibiotic Resistance Market Report Highlights

Complicated urinary tract infections segment accounted for significant share in 2023, on account of growing incidences of UTIs (urinary tract infections) globally

Oxazolidinones segment held the majority share in 2023, that is attributed to its greater efficacy and effectiveness against numerous drug-resistant bacteria or pathogens

Online pharmacies segment dominated the market in 2023, due to rising number of patients opting for remote consultation and popularity of e-prescriptions and digital health records

North America dominated the global market, owing to rising incidences of infectious diseases and development of new antibiotic solutions

The key market players include Johnson & Johnson Services, Merck & Co. Inc, Pfizer Inc., Novartis AG, The Medicines Company, and Achaogen Inc.

Polaris Market Research has segmented the antibiotic resistance market report based on disease, drug type, distribution channel, and region:

Antibiotic Resistance, Disease Outlook (Revenue - USD Billion, 2023 - 2032)

cUTI (Complicated Urinary Tract Infections)

CDI (Clostridioides Difficile Infection)

ABSSSI (Acute Bacterial Skin and Skin Structure Infections)

HABP (Hospital-acquired Bacterial Pneumonia)

CABP (Community-acquired Pneumonia)

cIAI (Complicated Intra-abdominal Infection)

BSI (Bloodstream Infection)

Antibiotic Resistance, Drug Class Outlook (Revenue - USD Billion, 2023 - 2032)

Oxazolidinones

Lipoglycopeptides

Tetracyclines

Combination Therapies

Cephalosporins

Others

Antibiotic Resistance, Distribution Channel Outlook (Revenue - USD Billion, 2023 - 2032)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Antibiotic Resistance, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa